Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA Given Concomitantly With PedvaxHIB and Infanrix in Healthy Children 15 Months of Age.

Trial Profile

An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA Given Concomitantly With PedvaxHIB and Infanrix in Healthy Children 15 Months of Age.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary) ; DTaP vaccine; Hib vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis A; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 Oct 2011 Primary endpoint 'Geometric-mean-antibody-titre' has been met.
    • 23 Oct 2011 Primary endpoint 'Antibody-levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top